Osteoporosis Treatment in Postmenopausal Women

First-Line Treatment Options

Bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab are appropriate first-line pharmacologic treatments for postmenopausal women with documented osteoporosis, effectively reducing the risk of hip and vertebral fractures, as recommended by the American College of Physicians based on high-quality evidence 1, 2, 3
The American College of Physicians strongly recommends these agents based on high-quality evidence showing they prevent further bone loss and reduce fracture risk 1, 3

Bone density monitoring is not recommended during the initial 5-year treatment period, and the recommended duration of initial therapy is 5 years, as suggested by the American College of Physicians 1, 3
The American College of Physicians recommends a 5-year initial therapy duration for denosumab 1, 3

Denosumab is generally well-tolerated with a favorable safety profile, but potential side effects include mild gastrointestinal symptoms, increased risk of infection and rash/eczema, as reported by the American College of Physicians 1, 3
Discontinuation of denosumab can lead to increased risk of multiple vertebral fractures due to rebound bone turnover, as warned by the American College of Physicians 4

Adequate calcium and vitamin D intake should accompany pharmacologic treatment, with recommended daily intake for a postmenopausal woman: 1,200 mg calcium and 600 IU vitamin D, as recommended by the American Academy of Family Physicians 5, 6, 7
Weight-bearing exercise, smoking cessation, and reducing alcohol intake should be encouraged, as suggested by the American Academy of Family Physicians 6, 7

Confirm osteoporosis diagnosis with T-score ≤ -2.5 on DEXA scan, as recommended by the American College of Physicians 1, 7
Plan for 5 years of initial therapy, and after 5 years, reassess fracture risk to determine if continued therapy is warranted, as suggested by the American College of Physicians 1, 3, 4, 5
If discontinuing denosumab, consider transitioning to a bisphosphonate to prevent rebound bone loss, as recommended by the American College of Physicians 4